endocrinology.org.access.web-sci.com:808/RevArtCom.htm Journal of Endocrinology 入口http://80-journals
endocrinology.org.access.web-sci.com:808/RevArtCom.htm Journal of Endocrinology 入口http://80-journals
特异性抗体药物,也是全球首个获批的PD-1/CTLA-4 免疫双抗,具有里程碑式的意义!中国自主研发抗癌药物崛起,从此国内病友也能接收到领先全球的抗癌新药治疗!来源:康方生物官网免疫治疗被誉为攻克癌症
0D/3kfOsZYVN+3PzX3/99ekJiDivE++g82GepYLyRv/Tg0Z/YOZ+5zrX2cGBvDNan1u6++RUl/cc1rqPFc+zc2MvcuH++fT55xra
0.06 SD [SE, 0.07] or 3.1 ms higher versus CC; 1-sided P=0.04) or additive model (0.06 SD [SE, 0.03